🇺🇸 FDA
Patent

US 10052363

Mesenchymal stem cells for the treatment of CNS diseases

granted A61KA61K35/12A61K35/28

Quick answer

US patent 10052363 (Mesenchymal stem cells for the treatment of CNS diseases) held by BRAINSTORM CELL THERAPEUTICS LTD. expires Mon Aug 16 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
BRAINSTORM CELL THERAPEUTICS LTD.
Grant date
Tue Aug 21 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 16 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
7
CPC classes
A61K, A61K35/12, A61K35/28, A61K38/185, A61P